PerkinElmer, Inc. (NYSE: PKI) stock rose over 2.7% on February 1st, 2019 (as of 11:51 am GMT-5; Source: Google finance) after the company posted better than expected results for the fourth quarter of FY18. The company has delivered the adjusted operating income from continuing operations for the quarter of $164.3 million, as compared to $135.3 million for the same period a year ago. Adjusted operating profit margin was 21.7% as a percentage of adjusted revenue. Net acquisitions grew approximately 13% and foreign exchange negatively impacted revenues by 2%. PKI finished the quarter with approximately $1.9 billion of debt and $163 million of cash. The company has completed the acquisition of Dani Analitica in Italy for $52 million, and the company repurchased approximately 650,000 shares of stock in the fourth quarter at an average per share purchase price of $80. Adjusted free cash flow of $132 million in the quarter saw strong sequential and year-over-year improvement, representing a 100% of cash net income. Meanwhile, over the last three years, the company has executed against the well-defined strategy to shift the portfolio across markets, customers and products. As a result of these changes, the company has entered 2019 with over 80% of the revenue in the diagnostics, food and life science end markets, up from 50% four years ago. With the environmental and industrial end markets now representing less than 20% of the revenue versus 45% in 2014. From a geographic reach perspective, emerging markets now account for 40% of the revenue, up from 28% four years ago. During the fourth quarter of FY 18, Diagnostics representing approximately 40% of total core sales grew 13% organically, driven by the reproductive health and immunodiagnostics business lines. Incorporating EUROIMMUN, Diagnostics would have grown 14% organically. Discovery & Analytical Solutions representing approximately 60% of total sales grew 5% organically in the fourth quarter. Core revenues saw growth in all major geographies during the fourth quarter with double-digit organic revenue growth in the Americas, high single-digit organic revenue growth in Asia, and low single-digit organic revenue growth in Europe. PKI in the fourth quarter of FY 18 has reported the adjusted earnings per share of $1.18, beating the analysts’ estimates for the adjusted earnings per share of $1.16. The company had reported the adjusted revenue growth of 18 percent to $756.5 million in the fourth quarter of FY 18, beating the analysts’ estimates for revenue by $9.65 million. This represents core organic growth of 7% excluding the impact from EUROIMMUN. For the full year 2019, the company expects GAAP earnings per share from continuing operations to be in a range of $2.93 to $2.98.

SOURCE : https://tradertalks-net.translate.goog/s/9981?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=auto&_x_tr_pto=wapp